Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

Objective The primary objective was to assess the effect of MVC intensification on latently infected CD4+ T cells in chronically HIV-1-infected patients receiving antiretroviral therapy. Methods We performed an open-label pilot phase II clinical trial involving chronically HIV-1-infected patients receiving stable antiretroviral therapy whose regimen was intensified with 48 weeks of maraviroc therapy. We analyzed the latent reservoir, the residual viremia and episomal 2LTR DNA to examine the relationship between these measures and the HIV-1 latent reservoir, immune activation, lymphocyte subsets (including effector and central memory T cells), and markers associated with bacterial translocation. Results Overall a non significant reduction in the size of the latent reservoir was found (p = 0.068). A mean reduction of 1.82 IUPM was observed in 4 patients with detectable latent reservoir at baseline after 48 weeks of intensification. No effect on plasma residual viremia was observed. Unexpectedly, all the patients had detectable 2LTR DNA circles at week 24, while none of them showed those circles at the end of the study. No changes were detected in CD4+ or CD8+ counts, although a significant decrease was found in the proportion of HLA-DR+/CD38+ CD4+ and CD8+ T-cells. LPS and sCD14 levels increased. Conclusions Intensification with MVC was associated with a trend to a decrease in the size of the latent HIV-1 reservoir in memory T cells. No impact on residual viremia was detected. Additional studies with larger samples are needed to confirm the results. Trial Registration ClinicalTrials.gov NCT00795444

[1]  Susan Moir,et al.  Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. , 2011, The Journal of infectious diseases.

[2]  R. Kaul,et al.  Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy , 2011, AIDS.

[3]  J. Farrar,et al.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. , 2011, AIDS.

[4]  John M. Coffin,et al.  Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells , 2011, Journal of Virology.

[5]  D. Fuchs,et al.  Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy , 2010, Journal of acquired immune deficiency syndromes.

[6]  C. B. Hare,et al.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. , 2010, The Journal of infectious diseases.

[7]  C. B. Hare,et al.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.

[8]  M. Lederman,et al.  Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients , 2010, PloS one.

[9]  M. Lederman,et al.  The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.

[10]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[11]  D. Cooper,et al.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. , 2010, The Journal of infectious diseases.

[12]  S J Gange,et al.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Siliciano,et al.  No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. , 2010, The Journal of infectious diseases.

[14]  R. Kaul,et al.  The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[15]  L. Palmisano,et al.  Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  Yuntao Wu,et al.  Chemokine Coreceptor Signaling in HIV-1 Infection and Pathogenesis , 2009, PLoS pathogens.

[17]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[18]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[19]  Raquel Lorente,et al.  The Spanish HIV BioBank: a model of cooperative HIV research , 2009, Retrovirology.

[20]  A. Trkola,et al.  HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.

[21]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[22]  R. Kaul,et al.  Immune reconstitution in the sigmoid colon after long-term HIV therapy , 2008, Mucosal Immunology.

[23]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[24]  D. Nickle,et al.  Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. , 2008, The Journal of infectious diseases.

[25]  Lawrence Corey,et al.  Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. , 2007, The Journal of infectious diseases.

[26]  O. Lambotte,et al.  Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo. , 2007, Journal of acquired immune deficiency syndromes.

[27]  Joseph A Kovacs,et al.  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.

[28]  P. Klenerman,et al.  Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ TEMRA Cells in Early Infection Are Linked to Control of HIV-1 Viremia and Predict the Subsequent Viral Load Set Point , 2007, Journal of Virology.

[29]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[30]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[31]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[32]  Daniel R. Kuritzkes,et al.  In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA , 2005, Journal of Virology.

[33]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[34]  Thomas C. Quinn,et al.  Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads , 2004, Journal of Virology.

[35]  Alan S Perelson,et al.  Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication , 2004, Journal of acquired immune deficiency syndromes.

[36]  Mario Clerici,et al.  Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years , 2003, Journal of Virology.

[37]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[38]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[39]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[40]  D. Kotler Characterization of intestinal disease associated with human immunodeficiency virus infection and response to antiretroviral therapy. , 1999, The Journal of infectious diseases.

[41]  M. Zeitz,et al.  Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. , 1999, Gastroenterology.

[42]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[44]  M. Zazzi,et al.  Evaluation of the presence of 2‐LTR HIV‐1 unintegrated DNA as a simple molecular predictor of disease progression , 1997, Journal of medical virology.

[45]  L. McQuay,et al.  Dilution assay statistics , 1994, Journal of clinical microbiology.

[46]  D. Douek,et al.  HIV infection and the gastrointestinal immune system , 2008, Mucosal Immunology.

[47]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.